Thymidylate synthase: A critical target for cancer chemotherapy

Clinical Colorectal Cancer

Volumn 1, Issue 4, 2002, Pages 220-229

  Rose, Michal G ^a   Farrell, Michael P ^a   Schmitz, John C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Fluorouracil; Capecitabine; Nolatrexed; Pemetrexed; Radiation therapy; Raltitrexed; ZD9331

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; CAPECITABINE; CARBOPLATIN; CISPLATIN; DNA; DOCETAXEL; FLUOROPYRIMIDINE CARBAMATE; FLUOROURACIL; FOLIC ACID DERIVATIVE; FOLINIC ACID; GEMCITABINE; GW 1843 U 89; IRINOTECAN; METESIND GLUCURONATE; METHOTREXATE; NOLATREXED; OXALIPLATIN; PEMETREXED; PLEVITREXED; RALTITREXED; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG; VAMIDEX;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AUSTRALIA; BLOOD TOXICITY; BREAST CANCER; CANADA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA SYNTHESIS; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; EUROPE; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; JAPAN; MESOTHELIOMA; NEPHROTOXICITY; OVARY CANCER; PANCREAS CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER; UNITED STATES;

EID: 0036217711     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2002.n.003     Document Type: Review

References (89)

1. Future challenges in the clinical development of thymidylate synthase inhibitor compounds
2. Antifolates
3. Fluorinated pyrimidines: A new class of tumor-inhibitory compounds
4. Fluorouracil: Biochemistry and pharmacology
5. Infusional 5-FU: Historical evolution, rationale, and clinical experience
6. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
7. Fluorouracil in colorectal cancer-a tale of two drugs: Implications for biochemical modulation
8. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
9. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer
10. Mechanisms of clinical resistance to 5-fluorouracil chemotherapy
11. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer
12. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy
13. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer
14. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
15. Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
16. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
17. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer
18. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
19. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy
20. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase
21. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers
22. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer
23. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil
24. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer
25. Transcriptional control elements and complex initiation pattern of the TATA-less bidirectional human thymidylate synthase promoter
26. Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA
27. Preclinical and clinical aspects of biomodulation of 5-fluorouracil
28. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Meta-Analysis Group in Cancer
29. Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients
30. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717
31. Folate-based thymidylate synthase inhibitors as anticancer drugs
32. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
33. Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase
34. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
35. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor
36. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
37. Raltitrexed (Tomudex") versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American trial
38. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed
39. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II-III randomized trial
40. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: Results of a phase I-II trial
41. Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer
42. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs
43. Overview of phase I trials of multitargeted antifolate (MTA, LY231514)
44. Overview of phase II trials of MTA in solid tumors
45. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
46. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial
47. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study
48. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial
49. Phase II study of ALIMTA single agent in patients with malignant pleural mesothelioma
50. Pemetrexed disodium (Alimta, LY231514, MTA) in locally advanced or metastatic breast cancer (MBC) patients (pts) with prior anthracycline or anthracenedione and taxane treatment: Phase II study
51. Efficacy and toxicity of pemetrexed disodium (Alimta) with folic acid (FA) in gastric cancer
52. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid
53. A phase study of the novel thymidylate synthase inhibitor 1842U89 with and without high dose oral folate
54. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase
55. Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors
56. Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks
57. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks
58. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations
59. Phase II trial of ZD9331 as third-line therapy for patients with ovarian carcinoma
60. ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: A phase II multicentre trial
61. ZD9331 plus topotecan in patients with refractory solid malignancies: A phase I dose-escalation study
62. AG-331, a "non-classical" Lipophilic thymidylate synthase inhibitor for the treatment of solid tumors
63. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion
64. A phase II trial of Thymitaq™ (AG337) in patients with squamous cell carcinoma of the head and neck
65. Preclinical and clinical studies of prolonged administration of the novel thymidylate synthase inhibitor, AG337
66. A phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma
67. A phase I study of the novel antifolate 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazole dihydrochloride (AG337) given by 24 hour intravenous continuous infusion
68. Oral fluoropyrimidine treatment of colorectal cancer
69. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
70. Oral fluoropyrimidines in cancer treatment
71. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
72. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
73. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
74. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
75. Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
76. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts
77. Phase I study of capecitabine combined with simultaneous radiotherapy for rectal cancer
78. A phase I study of capecitabine combined with radiotherapy for locally advanced potentially operable rectal cancer
79. Enhanced tumoricidal effect of preoperative chemoradiation using capecitabine for locally advanced rectal cancer
80. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
81. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer
82. Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxaliplatin in patients with advanced or metastatic solid tumours: Results from a phase I study
83. Oxaliplatin and capecitabine in advanced colorectal cancer: A dose-finding trial
84. Phase II study of capecitabine (CAP) + oxaliplatin (OXA) in first line and second line treatment of advanced or metastastic colorectal cancer (ACC)
85. Thymidylate synthase is localized to the nuclear periphery in the yeast Saccharomyces cerevisiae
86. Intracellular location of thymidylate synthase and its state of phosphorylation
87. The role of thymidylate synthase as an RNA binding protein
88. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex
89. Regulation of p53 expression by thymidylate synthase